摘要
目的研究利伐沙班在髋关节置换术后预防深静脉血栓形成的临床疗效。方法选择医院2009年1月至2011年1月行髋关节置换术的患者120例,随机分成两组(利伐沙班组和低分子肝素组),各60例。利伐沙班组在术后6 h口服10 mg利伐沙班,低分子肝素组在术后24 h内皮下注射40 mg低分子肝素,均每日1次,持续用药14 d。术后14 d对两组患者行下肢静脉彩色多普勒超声检查,比较两组深静脉血栓形成情况以及术后深静脉血栓发生率。结果低分子肝素组发生深静脉血栓9例,发生率为15.00%;利伐沙班组发生深静脉血栓2例,发生率为3.33%。两组比较差异有统计学意义(P<0.05)。利伐沙班组无不良反应发生。结论利伐沙班能有效预防髋关节置换术后深静脉血栓形成,且具有良好的安全性,值得临床推广。
Objective To study the clinical efficacy of rivaroxaban in the prevention of deep vein thrombosis after hip replacement. Methods A hundred and twenty patients with hip replacement surgery in our hospital from January 2009 to January 2011 were selected and randomly divided into two groups, the rivaroxaban and the low molecular weight heparin group, 60 cases in each group. The rivarox- aban group was given oral rivaroxaban 10 mg at 6 h after surgery, once daily for 14 successive 14 d, while the low molecular weight heparin group was given low molecular weight heparin 40 mg by subcutaneous injection within 24 h after operation, once daily for succes- sive 14 d. After 14 d treatment, the deep veins of lower extremities in the two groups were performed the color Doppler ultrasound examination. Then, the deep vein thrombosis and the incidence of postoperative deep vein thrombosis were compared between the two groups. Results Nine cases in the low molecular weight heparin group had deep vein thrombosis with the occurrence rate of 15.00%. Two cases in the rivaroxaban group had deep venous thrombosis with the occurrence rate of 3.33%. Two groups had statistically significant difference （P 〈 0. 05）. No adverse events occurred in the rivaroxaban group. Conclusion Rivaroxaban can effectively prevent deep vein thrombosis after hip replacement surgery, which has good security and is worthy of being popularized in clinic.
出处
《中国药业》
CAS
2012年第5期65-66,共2页
China Pharmaceuticals
关键词
利伐沙班
低分子肝素
髋关节置换术
预防
深静脉血栓
rivaroxaban
low molecular weight heparin
hip replacement
prevention
deep vein thrombosis
